Hipa.ai Research · Source: PubMed & ClinicalTrials.gov / AACT · Last updated:
The clinical evidence base for Vorasidenib comprises 12 peer-reviewed publications across 11 journals, 1 pivotal-trial primary-outcome rows reported to ClinicalTrials.gov, spanning indications including Glioma. Most recent publication: Vorasidenib in IDH1-mutant or IDH2-mutant low-grade glioma (INDIGO): secondary and exploratory endpoints from a randomised, double-blind, placebo-controlled, phase 3 trial., Lancet Oncol, 2025.
Curated set of pivotal-trial result papers and recent publications in high-tier journals.
Per-arm reported values from Phase 2/3 and Phase 3 trials with results posted to ClinicalTrials.gov.
| Trial | Indication | Primary endpoint | Arm | Value |
|---|---|---|---|---|
| NCT04164901 | Glioma | Progression-Free Survival (PFS) Up to approximately 30 months | Matching Placebo | 11.1 months |
| Vorasidenib | 27.7 months |
2005–2025: 12 publications.
Vorasidenib has been investigated in clinical trials for its potential use in treating glioma. A pivotal study, NCT04164901, focused on patients with glioma and evaluated a key measure known as Progression-Free Survival (PFS). PFS is an important endpoint in cancer research, reflecting the period during and after treatment when a patient lives without their disease worsening or without death. In this particular trial, the observation period for PFS extended up to approximately 30 months.
Within the NCT04164901 study, specific median Progression-Free Survival times were reported for the different treatment groups. Patients who received vorasidenib experienced a median PFS of 27.7 months. In comparison, patients in the placebo arm of the same NCT04164901 trial had a median PFS of 11.1 months.
All values presented are sourced from primary registry reporting. For comprehensive clinical information and informed decision-making, individual published papers should be consulted.
ctgov.study_references (PubMed PMIDs auto-attached by ClinicalTrials.gov to each trial), reference types RESULT, DERIVED, and BACKGROUND.ctgov.outcome_measurements joined to ctgov.design_outcomes where outcome_type = 'PRIMARY', restricted to phase PHASE3 and PHASE2/PHASE3.efetch.fcgi